SALIX
SpecialtySALIX is a specialty pharmaceutical company focused on Immunology, Gastroenterology, Oncology. Key products include TRULANCE.
SALIX's Key Drugs
SALIX's core commercial portfolio centers on TRULANCE, UCERIS, PLENVU, spanning Immunology and Gastroenterology — its most strategically important drugs approved in the last 15 years.
SALIX's Recent FDA Approvals
New NDA/BLA approvals for SALIX over the last two years — novel drugs only, excluding generics and label supplements.
SALIX's Therapeutic Areas
SALIX's approved drugs and pipeline span 3 therapeutic areas, led by Immunology and Gastroenterology, across 0 biologic and 5 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SALIX's Top Competitors
SALIX's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SALIX Pipeline Snapshot
Active clinical trials for SALIX across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TRULANCE leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling